ADVERUM BIOTECHNOLOGIES, INC.
100 Cardinal Way
Redwood City, California 94063
March 27, 2024
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3010
Attn: | Jason Drory |
RE: | Adverum Biotechnologies, Inc. |
Registration Statement on Form S-3 (File No. 333-278157)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Adverum Biotechnologies, Inc. (the Registrant) hereby requests that the Securities and Exchange Commission (the Commission) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-278157) (the Registration Statement) to become effective on Friday, March 29, 2024, at 4:30 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Kenneth Guernsey and Julia Boesch of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Julia Boesch of Cooley LLP, counsel to the Registrant, at (415) 693-2326, or in her absence, Kenneth Guernsey at (415) 693-2091.
[Remainder of page intentionally left blank]
Very truly yours, | ||
ADVERUM BIOTECHNOLOGIES, INC. | ||
By: | /s/ Linda Rubinstein | |
Name: | Linda Rubinstein | |
Title: | Chief Financial Officer |
cc: | Kenneth Guernsey, Cooley LLP |
Julia Boesch, Cooley LLP